An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
Related Posts
Trump says Iran would be ‘obliterated’ if it assassinated him – National | Globalnews.ca
February 4, 2025
9:16 pm